Magnetic resonance imaging (MRI) and positron emission tomography (PET)/MRI for lung cancer staging

Journal of Thoracic Imaging

Volumn 31, Issue 4, 2016, Pages 215-227

  Ohno, Yoshiharu ^a   Koyama, Hisanobu ^a   Lee, Ho Yun ^a,b,c   Yoshikawa, Takeshi ^a   Sugimura, Kazuro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Samsung Medical Center   (South Korea)

Author keywords

Lung cancer; Magnetic resonance imaging; Positron emission tomography computed tomography; Positron emission tomography magnetic resonance imaging; Staging

Indexed keywords

CANCER SCINTISCANNING; CANCER STAGING; CLINICAL PRACTICE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; HUMAN; LUNG CANCER; LUNG SCINTISCANNING; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PET SCANNER; PET-CT SCANNER; PET-MRI SCANNER; POSITRON EMISSION TOMOGRAPHY; THORAX RADIOGRAPHY; WHOLE BODY MRI; WHOLE BODY PET; WHOLE BODY SCINTISCANNING; DIAGNOSTIC IMAGING; LUNG; LUNG TUMOR; MULTIMODAL IMAGING; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

FLUORODEOXYGLUCOSE F18; HUMANS; LUNG; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MULTIMODAL IMAGING; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84963706179     PISSN: 08835993     EISSN: 15360237     Source Type: Journal    
DOI: 10.1097/RTI.0000000000000210     Document Type: Conference Paper

References (87)

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9-29.
2. Spiro SG, Silvestri GA. One hundred years of lung cancer. Am J Respir Crit Care Med. 2005;172:523-529.
3. Spiro SG, Tanner NT, Silvestri GA, et al. Lung cancer: progress in diagnosis, staging and therapy. Respirology. 2010;15:44-50.
4. Howington JA, Blum MG, Chang AC, et al. Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(suppl):e278S-e313S.
5. Ramnath N, Dilling TJ, Harris LJ, et al. Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidencebased clinical practice guidelines. Chest. 2013;143(suppl):e314S-e340S.
6. Socinski MA, Evans T, Gettinger S, et al. Treatment of stage IV non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(suppl):e341S-e368S.
7. Jett JR, Schild SE, Kesler KA, et al. Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(suppl):e400S-e419S.
8. Travis WD, Giroux DJ, Chansky K, et al. International Staging Committee and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2008;3:1213-1223.
9. Sobin LH, Gospodarowicz MK, Wittekind C, et al. UICC TNM Classification of Malignant Tumours. New York, NY: Wiley-Liss; 2009.
10. von Schulthess GK, Veit-Haibach P. Workflow considerations in PET/MR imaging. J Nucl Med. 2014;55(suppl 2):19S-24S.
11. von Schulthess GK, Schlemmer HP. A look ahead: PET/MR versus PET/CT. Eur J Nucl Med Mol Imaging. 2009;36(suppl 1):S3-S9.
12. Torigian DA, Zaidi H, Kwee TC, et al. PET/MR imaging: technical aspects and potential clinical applications. Radiology. 2013;267:26-44.
13. Vaska P, Cao T. The state of instrumentation for combined positron emission tomography and magnetic resonance imaging. Semin Nucl Med. 2013;43:11-18.
14. Catana C, Guimaraes AR, Rosen BR. PET and MR imaging: the odd couple or a match made in heaven? J Nucl Med. 2013;54:815-824.
15. von Schulthess GK, Kuhn FP, Kaufmann P, et al. Clinical positron emission tomography/magnetic resonance imaging applications. Semin Nucl Med. 2013;43:3-10.
16. Yoon SH, Goo JM, Lee SM, et al. Positron emission tomography/magnetic resonance imaging evaluation of lung cancer: current status and future prospects. J Thorac Imaging. 2014;29:4-16.
17. Yoo HJ, Lee JS, Lee JM. Integrated whole body MR/PET: where are we? Korean J Radiol. 2015;16:32-49.
18. Ohno Y, Koyama H, Nogami M, et al. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. J Magn Reson Imaging. 2007;26:498-509.
19. Yi CA, Shin KM, Lee KS, et al. Non-small cell lung cancer staging: efficacy comparison of integrated PET/CT versus 3.0-T whole-body MR imaging. Radiology. 2008;248: 632-642.
20. Ohno Y, Koyama H, Onishi Y, et al. Non-small cell lung cancer: whole-body MR examination for M-stage assessment-utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology. 2008;248:643-654.
21. Takenaka D, Ohno Y, Matsumoto K, et al. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging. 2009;30: 298-308.
22. Heusner TA, Kuemmel S, Koeninger A, et al. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging. Eur J Nucl Med Mol Imaging. 2010;37:1077-1086.
23. Sommer G, Wiese M, Winter L, et al. Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography. Eur Radiol. 2012;22:2859-2867.
24. Yi CA, Lee KS, Lee HY, et al. Coregistered whole body magnetic resonance imaging-positron emission tomography (MRI-PET) versus PET-computed tomography plus brain MRI in staging resectable lung cancer: comparisons of clinical effectiveness in a randomized trial. Cancer. 2013;119:1784-1791.
25. Ohno Y, Nishio M, Koyama H, et al. Comparison of the utility of whole-body MRI with and without contrast-enhanced Quick 3D and double RF fat suppression techniques, conventional whole-body MRI, PET/CT and conventional examination for assessment of recurrence in NSCLC patients. Eur J Radiol. 2013;82:2018-2027.
26. Ohno Y, Koyama H, Yoshikawa T, et al. Three-way comparison of whole-body MR, coregistered whole-body FDG PET/MR, and integrated whole-body FDG PET/CT imaging: TNM and stage assessment capability for non-small cell lung cancer patients. Radiology. 2015;275:849-861.
27. Bailey DL. Transmission scanning in emission tomography. Eur J Nucl Med. 1998;25:774-787.
28. Zaidi H, Hasegawa B. Determination of the attenuation map in emission tomography. J Nucl Med. 2003;44:291-315.
29. Ollinger JM. Model-based scatter correction for fully 3D PET. Phys Med Biol. 1996;41:153-176.
30. Burger C, Goerres G, Schoenes S, et al. PET attenuation coefficients from CT images: experimental evaluation of the transformation of CT into PET 511-keV attenuation coefficients. Eur J Nucl Med Mol Imaging. 2002;29:922-927.
31. Kinahan PE, Hasegawa BH, Beyer T. X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med. 2003;33:166-179.
32. Townsend DW. Dual-modality imaging: combining anatomy and function. J Nucl Med. 2008;49:938-955.
33. Montandon ML, Zaidi H. Atlas-guided non-uniform attenuation correction in cerebral 3D PET imaging. Neuroimage. 2005;25:278-286.
34. Kim JS, Lee JS, Park MH, et al. Feasibility of template-guided attenuation correction in cat brain PET imaging. Mol Imaging Biol. 2010;12:250-258.
35. Berker Y, Franke J, Salomon A, et al. MRI-based attenuation correction for hybrid PET/MRI systems: a 4-class tissue segmentation technique using a combined ultrashort-echotime/Dixon MRI sequence. J Nucl Med. 2012;53:796-804.
36. Boss A, Stegger L, Bisdas S, et al. Feasibility of simultaneous PET/MR imaging in the head and upper neck area. Eur Radiol. 2011;21:1439-1446.
37. Hofmann M, Steinke F, Scheel V, et al. MRI-based attenuation correction for PET/MRI: a novel approach combining pattern recognition and atlas registration. J Nucl Med. 2008;49:1875-1883.
38. Hofmann M, Bezrukov I, Mantlik F, et al. MRI-based attenuation correction for whole-body PET/MRI: quantitative evaluation of segmentation-and atlas-based methods. J Nucl Med. 2011;52:1392-1399.
39. Martinez-Möller A, Souvatzoglou M, Delso G, et al. Tissue classification as a potential approach for attenuation correction in whole-body PET/MRI: evaluation with PET/CT data. J Nucl Med. 2009;50:520-526.
40. Keereman V, Fierens Y, Broux T, et al. MRI-based attenuation correction for PET/MRI using ultrashort echo time sequences. J Nucl Med. 2010;51:812-818.
41. Schulz V, Torres-Espallardo I, Renisch S, et al. Automatic, three-segment, MR-based attenuation correction for wholebody PET/MR data. Eur J Nucl Med Mol Imaging. 2011;38: 138-152.
42. Eiber M, Martinez-Möller A, Souvatzoglou M, et al. Value of a Dixon-based MR/PET attenuation correction sequence for the localization and evaluation of PET-positive lesions. Eur J Nucl Med Mol Imaging. 2011;38:1691-1701.
43. Kim JH, Lee JS, Song IC, et al. Comparison of segmentationbased attenuation correction methods for PET/MRI: evaluation of bone and liver standardized uptake value with oncologic PET/CT data. J Nucl Med. 2012;53:1878-1882.
44. Eiber M, Takei T, Souvatzoglou M, et al. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions. J Nucl Med. 2014;55:191-197.
45. Andersen FL, Ladefoged CN, Beyer T, et al. Combined PET/MR imaging in neurology: MR-based attenuation correction implies a strong spatial bias when ignoring bone. Neuroimage. 2014;84:206-216.
46. Catana C, van der Kouwe A, Benner T, et al. Toward implementing an MRI-based PET attenuation-correction method for neurologic studies on the MR-PET brain prototype. J Nucl Med. 2010;51:1431-1438.
47. Aitken AP, Giese D, Tsoumpas C, et al. Improved UTE-based attenuation correction for cranial PET-MR using dynamic magnetic field monitoring. Med Phys. 2014;41:012302.
48. Dickson JC, O'Meara C, Barnes A. A comparison of CT-and MR-based attenuation correction in neurological PET. Eur J Nucl Med Mol Imaging. 2014;41:1176-1189.
49. Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology. 1991;178:705-713.
50. Ohno Y, Sugimura K, Hatabu H. MR imaging of lung cancer. Eur J Radiol. 2002;44:172-181.
51. Kwee TC, Takahara T, Ochiai R, et al. Complementary roles of whole-body diffusion-weighted MRI and 18F-FDG PET: the state of the art and potential applications. J Nucl Med. 2010;51:1549-1558.
52. Sieren JC, Ohno Y, Koyama H, et al. Recent technological and application developments in computed tomography and magnetic resonance imaging for improved pulmonary nodule detection and lung cancer staging. J Magn Reson Imaging. 2010;32:1353-1369.
53. Koyama H, Ohno Y, Seki S, et al. Magnetic resonance imaging for lung cancer. J Thorac Imaging. 2013;28:138-150.
54. Ohno Y. New applications of magnetic resonance imaging for thoracic oncology. Semin Respir Crit Care Med. 2014;35:27-40.
55. Ohno Y, Koyama H, Yoshikawa T, et al. Lung cancer assessment using MR imaging: an update. Magn Reson Imaging Clin N Am. 2015;23:231-244.
56. Sakai S,Murayama S,Murakami J, et al. Bronchogenic carcinoma invasion of the chest wall: evaluation with dynamic cine MRI during breathing. J Comput Assist Tomogr. 1997;21:595-600.
57. Murata K, Takahashi M, Mori M, et al. Chest wall and mediastinal invasion by lung cancer: evaluation with multisection expiratory dynamic CT. Radiology. 1994;191:251-255.
58. Takahashi K, Furuse M, Hanaoka H, et al. Pulmonary vein and left atrial invasion by lung cancer: assessment by breathhold gadolinium-enhanced three-dimensional MR angiography. J Comput Assist Tomogr. 2000;24:557-561.
59. Ohno Y, Adachi S, Motoyama A, et al. Multiphase ECGtriggered 3D contrast-enhanced MR angiography: utility for evaluation of hilar and mediastinal invasion of bronchogenic carcinoma. J Magn Reson Imaging. 2001;13:215-224.
60. Higashino T, Ohno Y, Takenaka D, et al. Thin-section multiplanar reformats from multidetector-row CT data: utility for assessment of regional tumor extent in non-small cell lung cancer. Eur J Radiol. 2005;56:48-55.
61. Huellner MW, de Galiza Barbosa F, Husmann L, et al. TNM staging of non-small cell lung cancer: comparison of PET/MR and PET/CT. J Nucl Med. 2016;57:21-26.
62. Boiselle PM, Patz EF Jr, Vining DJ, et al. Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. Radiographics. 1998;18:1061-1069.
63. Takenaka D, Ohno Y, Hatabu H, et al. Differentiation of metastatic versus non-metastatic mediastinal lymph nodes in patients with non-small cell lung cancer using respiratorytriggered short inversion time inversion recovery (STIR) turbo spin-echo MR imaging. Eur J Radiol. 2002;44:216-224.
64. Ohno Y, Hatabu H, Takenaka D, et al. Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative and qualitative assessment with STIR turbo spin-echo MR imaging. Radiology. 2004;231: 872-879.
65. Ohno Y, Koyama H, Nogami M, et al. STIR turbo SE MR imaging vs. coregistered FDG-PET/CT: quantitative and qualitative assessment of N-stage in non-small-cell lung cancer patients. J Magn Reson Imaging. 2007;26:1071-1080.
66. Morikawa M, Demura Y, Ishizaki T, et al. The effectiveness of 18F-FDG PET/CT combined with STIR MRI for diagnosing nodal involvement in the thorax. J Nucl Med. 2009;50:81-87.
67. Ohno Y, Koyama H, Yoshikawa T, et al. N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT. Radiology. 2011;261:605-615.
68. Nomori H, Mori T, Ikeda K, et al. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J Thorac Cardiovasc Surg. 2008;135:816-822.
69. Hasegawa I, Boiselle PM, Kuwabara K, et al. Mediastinal lymph nodes in patients with non-small cell lung cancer: preliminary experience with diffusion-weighted MR imaging. J Thorac Imaging. 2008;23:157-161.
70. Pauls S, Schmidt SA, Juchems MS, et al. Diffusion-weighted MR imaging in comparison to integrated [18F]-FDG PET/CT for N-staging in patients with lung cancer. Eur J Radiol. 2012; 81:178-182.
71. Xu L, Tian J, Liu Y, et al. Accuracy of diffusion-weighted (DW)MRI with background signal suppression (MR-DWIBS) in diagnosis of mediastinal lymph node metastasis of nonsmallcell lung cancer (NSCLC). J Magn Reson Imaging. 2014;40: 200-205.
72. Ohno Y, Koyama H, Yoshikawa T, et al. Diffusion-weighted MR imaging using FASE sequence for 3T MR system: Preliminary comparison of capability for N-stage assessment by means of diffusion-weighted MR imaging using EPI sequence, STIR FASE imaging and FDG PET/CT for nonsmall cell lung cancer patients. Eur J Radiol. 2015;84:2321-2331.
73. Feuerstein IM, Jicha DL, Pass HI, et al. Pulmonary metastases: MR imaging with surgical correlation - a prospective study. Radiology. 1992;182:123-129.
74. Kersjes W, Mayer E, Buchenroth M, et al. Diagnosis of pulmonary metastases with turbo-SE MR imaging. Eur Radiol. 1997;7:1190-1194.
75. Schroeder T, Ruehm SG, Debatin JF, et al. Detection of pulmonary nodules using a 2D HASTE MR sequence: comparison with MDCT. Am J Roentgenol. 2005;185:979-984.
76. Both M, Schultze J, Reuter M, et al. Fast T1-and T2-weighted pulmonary MR-imaging in patients with bronchial carcinoma. Eur J Radiol. 2005;53:478-488.
77. Regier M, Kandel S, Kaul MG, et al. Detection of small pulmonary nodules in high-field MR at 3T: evaluation of different pulse sequences using porcine lung explants. Eur Radiol. 2007;17:1341-1351.
78. Bruegel M, Gaa J, Woertler K, et al. MRI of the lung: value of different turbo spin-echo, single-shot turbo spin-echo, and 3D gradient-echo pulse sequences for the detection of pulmonary metastases. J Magn Reson Imaging. 2007;25:73-81.
79. Yi CA, Jeon TY, Lee KS, et al. 3-T MRI: usefulness for evaluating primary lung cancer and small nodules in lobes not containing primary tumors. Am J Roentgenol. 2007;189: 386-392.
80. Frericks BB, Meyer BC, Martus P, et al. MRI of the thorax during whole-body MRI: evaluation of different MR sequences and comparison to thoracic multidetector computed tomography (MDCT). J Magn Reson Imaging. 2008;27: 538-545.
81. Koyama H, Ohno Y, Kono A, et al. Quantitative and qualitative assessment of non-contrast-enhanced pulmonary MR imaging for management of pulmonary nodules in 161 subjects. Eur Radiol. 2008;18:2120-2231.
82. Sommer G, Tremper J, Koenigkam-Santos M, et al. Lung nodule detection in a high-risk population: comparison of magnetic resonance imaging and low-dose computed tomography. Eur J Radiol. 2014;83:600-605.
83. Ohno Y, Koyama H, Yoshikawa T, et al. Pulmonary highresolution ultrashort TE MR imaging: comparison with thinsection standard-and low-dose computed tomography for the assessment of pulmonary parenchyma diseases. J Magn Reson Imaging. 2016;43:512-532.
84. Gámez C, Rosell R, Ferná ndez A, et al. PET/CT fusion scan in lung cancer: current recommendations and innovations. J Thorac Oncol. 2006;1:74-77.
85. Silvestri GA, Gould MK, Margolis ML, et al. American College of Chest Physicians. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132(suppl):178S-201S.
86. Samson DJ, Seidenfeld J, Simon GR, et al. American College of Chest Physicians. Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(suppl):314S-323S.
87. Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(suppl):e211S-e215S.